First author [ref.] | Treatment arm | Patients n | Objective response % | p-value | Median progression-free survival months | p-value | Median survival months | p-value |
Maemondo [9] and Inoue [10] | Gefitinib | 114 | 73 | <0.001 | 10.8 | <0.001 | 27.7 | 0.483 |
Carboplatin+ paclitaxel | 114 | 30 | 5.4 | 26.6 | ||||
Mitsudomi [11] | Gefitinib | 86 | 62 | <0.0001 | 9.2 | <0.0001 | Not reached | 0.211 |
Cisplatin+ docetaxel | 86 | 32 | 6.3 | 30.9 | ||||
Zhou [12] | Erlotinib | 83 | 82 | <0.0001 | 13.1 | <0.0001 | 22.7 | ns |
Gemcitabine+ carboplatin | 82 | 36 | 4.6 | 28.9 | ||||
Rosell [13] | Erlotinib | 86 | 58 | <0.0001 | 9.7 | <0.0001 | 19.3 | 0.87 |
Standard chemotherapy | 87 | 15 | 5.2 | 19.5 | ||||
Sequist [14] | Afatinib | 230 | 56 | 0.001 | 11.1 | 0.001 | Not reached | 0.60 |
Cisplatin+ pemetrexed | 115 | 23 | 6.9 | |||||
Wu [15] | Afatinib | 242 | 67 | <0.0001 | 11 | <0.0001 | 22.1 | 0.76 |
Gemcitabine+ cisplatin | 122 | 23 | 5.6 | 22.2 |
ns: nonsignificant.